US biotech Inovio (Nasdaq: INO) said it plans to offer and sell shares of its common stock in an underwritten public offering ...

Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review ...

Investing.com -- INOVIO Pharmaceuticals Inc. (NASDAQ:INO) shares fell 10% after the biotechnology company announced the pricing of an underwritten public offering at $1.90 per share, representing a ...

Pharmaceuticals announced the pricing of an underwritten public offering of 13,158,000 shares of its common stock at a public ...

Chief Medical Officer Michael Sumner reported the BLA rolling submission was completed on October 30 and that the submission “clearly articulates the clinical efficacy of 3107 and demonstrates a ...

Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Monday, November 10, 2025.

Pharmaceuticals announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the ...

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and ...

The stock's rise snapped a four-day losing streak.

Inovio Pharmaceuticals Inc. INO) on Monday reported a loss of $45.5 million in its third quarter.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, ...

Shares of Inovio Pharmaceuticals Inc. INO shed 2.88% to $2.36 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.57 ...